Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Erdmann
Erland
E
Medizinische Klinik III der Universität zu Köln, Köln, Germany. erland.erdmann@uni-koeln.de
Spanheimer
Robert
R
Charbonnel
Bernard
B